Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of CRS + HIPEC with Mitomycin-C for Peritoneal Carcinomatosis
NCT02040142Phase 2Completed
- Sponsor
- Albert Einstein College of Medicine
- Start
- Nov 2011
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitomycin c in peritoneal carcinomatosis (PC), sponsored by Albert Einstein College of Medicine. Primary endpoints: Completeness of Cytoreduction at 12 months and Perioperative and Postoperative Morbidity and Mortality at 30 days. Started Nov 2011; status: completed.
02
Drugs
mitomycin c
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT02040142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040142.